<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467933</url>
  </required_header>
  <id_info>
    <org_study_id>JPAL-LETTERS-SEROQUEL</org_study_id>
    <nct_id>NCT02467933</nct_id>
  </id_info>
  <brief_title>The Effect of Informative Letters on the Prescription and Receipt of Seroquel</brief_title>
  <official_title>The Effect of Informative Letters on the Prescription and Receipt of Seroquel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdul Latif Jameel Poverty Action Lab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Medicare and Medicaid Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Services Administration (GSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Abdul Latif Jameel Poverty Action Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abusive prescribing exposes patients to unnecessary health risks and results in wasteful
      public expenditures. This study will evaluate an innovative approach to fighting abusive
      prescription: sending letters to suspected inappropriate prescribers warning them that they
      are outliers compared to their peers and have been flagged for review. The study will target
      high prescribers of Seroquel (Quetiapine), an atypical antipsychotic. Using claims data, the
      investigators will assess the effect of the letters on prescribing of Seroquel, receipt of
      Seroquel by patients, substitution behavior by prescribers and patients, and health outcomes
      of patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>9 months</time_frame>
    <description>The prescribing of Seroquel over the 9 months following the initial sending of the letters. Prescribing is defined as the total &quot;days supply&quot; of Seroquel attributed to the prescriber, expressed in &quot;30-day equivalents&quot; i.e. divided by 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day equivalent prescribing of Seroquel treatments</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5055</enrollment>
  <condition>Economics</condition>
  <condition>Fraud</condition>
  <condition>Delivery of Health Care</condition>
  <condition>Health Expenditures</condition>
  <condition>Centers for Medicare and Medicaid Services (U.S.)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm receives a placebo letter unrelated to Seroquel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Informative Letter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo letter</intervention_name>
    <description>The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initial Informative letter</intervention_name>
    <description>The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
    <arm_group_label>Informative Letter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Followup Informative Letter</intervention_name>
    <description>The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.</description>
    <arm_group_label>Informative Letter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General care practitioner

          -  Outlier with respect to the count of Seroquel prescription drug treatments relative to
             peer group of prescribers in 2013 and 2014

          -  Outlier with respect to the count of Seroquel 30-day equivalent prescription drug
             treatments relative to peer group of prescribers in 2013 and 2014

        Exclusion Criteria:

          -  Deceased
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Sacarny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <link>
    <url>https://www.socialscienceregistry.org/trials/729</url>
    <description>American Economic Association Randomized Controlled Trials Registry Entry</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>449</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.socialscienceregistry.org/trials/729</doc_url>
      <doc_comment>Study protocol archived on American Economic Association Social Science Registry page.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>448</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.socialscienceregistry.org/trials/729</doc_url>
      <doc_comment>Pre-specified analysis plan archived on American Economic Association Social Science Registry page.
Final version prior to unblinding: Version 2.0 (March 5, 2016)</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

